These observations suggest selectively targeting NRF2 or its downstream pathways in macrophages could overcome resistance and reinstate the positive T-cell macrophage crosstalk, which is crucial for robust tumor immunity.36 The gene discussed is NFE2L2; the disease is neoplasm.